BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

596 related articles for article (PubMed ID: 20696318)

  • 1. Role of post-translational modifications in modulating the structure, function and toxicity of alpha-synuclein: implications for Parkinson's disease pathogenesis and therapies.
    Oueslati A; Fournier M; Lashuel HA
    Prog Brain Res; 2010; 183():115-45. PubMed ID: 20696318
    [TBL] [Abstract][Full Text] [Related]  

  • 2. α-Synuclein aggregation and modulating factors.
    Paleologou KE; El-Agnaf OM
    Subcell Biochem; 2012; 65():109-64. PubMed ID: 23225002
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms of Parkinson's disease linked to pathological alpha-synuclein: new targets for drug discovery.
    Lee VM; Trojanowski JQ
    Neuron; 2006 Oct; 52(1):33-8. PubMed ID: 17015225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aggregation of alpha-synuclein in the pathogenesis of Parkinson's disease.
    Iwatsubo T
    J Neurol; 2003 Oct; 250 Suppl 3():III11-4. PubMed ID: 14579119
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of ubiquitin linkages on alpha-synuclein induced-toxicity in a Drosophila model of Parkinson's disease.
    Lee FK; Wong AK; Lee YW; Wan OW; Chan HY; Chung KK
    J Neurochem; 2009 Jul; 110(1):208-19. PubMed ID: 19457126
    [TBL] [Abstract][Full Text] [Related]  

  • 6. alpha -Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease.
    Lo Bianco C; Ridet JL; Schneider BL; Deglon N; Aebischer P
    Proc Natl Acad Sci U S A; 2002 Aug; 99(16):10813-8. PubMed ID: 12122208
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Generation of a alpha-synuclein-based rat model of Parkinson's disease.
    Recchia A; Rota D; Debetto P; Peroni D; Guidolin D; Negro A; Skaper SD; Giusti P
    Neurobiol Dis; 2008 Apr; 30(1):8-18. PubMed ID: 18313315
    [TBL] [Abstract][Full Text] [Related]  

  • 8. α-Synuclein phosphorylation as a therapeutic target in Parkinson's disease.
    Braithwaite SP; Stock JB; Mouradian MM
    Rev Neurosci; 2012 Mar; 23(2):191-8. PubMed ID: 22499677
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Controlling the mass action of alpha-synuclein in Parkinson's disease.
    Kim C; Lee SJ
    J Neurochem; 2008 Oct; 107(2):303-16. PubMed ID: 18691382
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exploring the Roles of Post-Translational Modifications in the Pathogenesis of Parkinson's Disease Using Synthetic and Semisynthetic Modified α-Synuclein.
    Chen H; Zhao YF; Chen YX; Li YM
    ACS Chem Neurosci; 2019 Feb; 10(2):910-921. PubMed ID: 30628768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beyond α-synuclein transfer: pathology propagation in Parkinson's disease.
    Hansen C; Li JY
    Trends Mol Med; 2012 May; 18(5):248-55. PubMed ID: 22503115
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of post-translational modifications on the alpha-synuclein aggregation-related pathogenesis of Parkinson's disease.
    Yoo H; Lee J; Kim B; Moon H; Jeong H; Lee K; Song WJ; Hur JK; Oh Y
    BMB Rep; 2022 Jul; 55(7):323-335. PubMed ID: 35733294
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heat-mediated enrichment of α-synuclein from cells and tissue for assessing post-translational modifications.
    Vicente Miranda H; Xiang W; de Oliveira RM; Simões T; Pimentel J; Klucken J; Penque D; Outeiro TF
    J Neurochem; 2013 Sep; 126(5):673-84. PubMed ID: 23534813
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Implication of Alpha-Synuclein Phosphorylation at S129 in Synucleinopathies: What Have We Learned in the Last Decade?
    Oueslati A
    J Parkinsons Dis; 2016; 6(1):39-51. PubMed ID: 27003784
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathological roles of α-synuclein in neurological disorders.
    Vekrellis K; Xilouri M; Emmanouilidou E; Rideout HJ; Stefanis L
    Lancet Neurol; 2011 Nov; 10(11):1015-25. PubMed ID: 22014436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of Ser129 phosphorylation of α-synuclein in neurodegeneration of Parkinson's disease: a review of in vivo models.
    Sato H; Kato T; Arawaka S
    Rev Neurosci; 2013; 24(2):115-23. PubMed ID: 23314528
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Post-translational modification of α-synuclein in Parkinson's disease.
    Barrett PJ; Timothy Greenamyre J
    Brain Res; 2015 Dec; 1628(Pt B):247-253. PubMed ID: 26080075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Familial Mutations and Post-translational Modifications of UCH-L1 in Parkinson's Disease and Neurodegenerative Disorders.
    Lee YC; Hsu SD
    Curr Protein Pept Sci; 2017; 18(7):733-745. PubMed ID: 26899237
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of rotenone-induced modifications in alpha-synuclein using affinity pull-down and tandem mass spectrometry.
    Mirzaei H; Schieler JL; Rochet JC; Regnier F
    Anal Chem; 2006 Apr; 78(7):2422-31. PubMed ID: 16579629
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of posttranslational modifications of α-synuclein and LRRK2 in Parkinson's disease: Potential contributions of environmental factors.
    Pajarillo E; Rizor A; Lee J; Aschner M; Lee E
    Biochim Biophys Acta Mol Basis Dis; 2019 Aug; 1865(8):1992-2000. PubMed ID: 30481588
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.